Navigation Links
Generic Products Compete With GlaxoSmithKline

Stiff competition offered by generic drug makers may well eat into the profit figures of GlaxoSmithKline, according to company sources. The Cox-2 painkiller of the organization is also likely to suffer as a result of this.// The company is also embroiled in a tax related dispute with the Government in the US. The sales of the company for the year rose by13% at £21.6 billion, while its earnings were at £6.7 billion.

The sales of Advair, an asthma drug rose to £851 million during the 2005 last quarter, in spite of the US Food and Drug Administration (FDA) expressing strong reservations with regard to the drug. The sales figure for Avandia was at £289 million for the same quarter, while Avandamet crossed the £46 million figure.

The management chose to be cautious with regard to the 2006 earnings as a result of low priced generic competitors for the antidepressant Wellbutrin XL, hay fever medication Flonase, and Zofran. The per share earnings for 2006 is forecast at only 10% by the company. The results of the Cox-2 painkiller’s phase-III tests are also not very encouraging, according to the management of GlaxoSmithKline. Further development with regard to the drug however is being undertaken.

As many as another seven medicines are expected to be launched in 2006, which are inclusive of Entereg, Arranon, and Avandaryl. The regulators will be called upon to give their approval for seven more medicines also, which is inclusive of an anti H5N1 bird flu vaccine. The organization is also seeking to make some acquisitions during the course of the year. The consumer healthcare business of Pfizer is reported to be one among the targets of the compay.
'"/>




Page: 1

Related medicine news :

1. Generic drug costs remain shackled
2. FDA Approves Indian Generic Drug For AIDS Treatment
3. Proper Validation of Generic Drugs Could Save Millions of AIDS Patients
4. AIDS Generic Drugs Approved by FDA for Sale in US
5. HIV Mortality declining in India due to Generic Antiretroviral therapy drugs
6. Generic Drugs Usage In US Can Save $20 Billion – Express Script Surve
7. ViroPharma Shares Fall As FDA Moves Towards Generic Vancocin
8. Ranbaxy Expands By Acquiring A Generic Company In Belgium
9. First Generic Version of Lexapro permitted by US
10. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
11. Ranbaxy Acquires Glaxosmithklines Generic Unit in Spain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: